RxDoctor Payments Data

Lawrence Kohn, MD

Internal Medicine · Naples, FLNPI 1407838519

Payments from drug & device makers

$847in general payments, 2019–2025

Across 43 payments — averaging $19.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$127
  • Corcept Therapeutics$93
  • AbbVie$67
  • Eisai Inc.$61
  • Johnson & Johnson$57
  • GSK$50
  • plus $393 from 14 others

What the payments were for

  • Food & beverage$847100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$847 in reported general payments places this provider in the 65th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$317,052
Medicare patients
989
Services billed
4,365

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin309$454,755
EliquisApixaban219$278,652
MounjaroTirzepatide205$233,425
OzempicSemaglutide136$222,110
FarxigaDapagliflozin Propanediol81$112,206
TrulicityDulaglutide51$66,176
JanuviaSitagliptin Phosphate47$61,994
XareltoRivaroxaban32$49,479
RybelsusSemaglutide16$41,403
Tresiba Flextouch U-200Insulin Degludec32$35,085
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog21$27,636
VascepaIcosapent Ethyl26$26,386
Repatha SureclickEvolocumab22$25,478
WegovySemaglutide15$23,798
TradjentaLinagliptin16$21,749

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$18$476,504325 claims
Lilly USA, LLCMounjaro, Trulicity$28$299,601256 claims
Novo NordiskOzempic, Rybelsus, Wegovy, Novolog$127$292,610179 claims
PfizerEliquis$32$278,652219 claims
MerckJanuvia$15$61,99447 claims
Johnson & JohnsonXarelto$57$49,47932 claims
GSKTrelegy Ellipta, Breo Ellipta$50$29,39648 claims
AbbVieSynthroid$67$11,476168 claims
Esperion Therapeutics, Inc.Nexlizet$16$4,41211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Naples

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →